Arvinas and Pfizer to out-license vepdegestrant; cuts 15% workforce, authorizes $100M buyback

ARVINAS, INC.

Plans to out-license vepdegestrant commercialization rights to a third party; PDUFA date June 5, 2026.
Additional workforce reduction of 15%; expects $4.5M severance costs in Q3/Q4 2025.
Total annual cost savings expected to exceed $100M compared to FY 2024, including prior actions.
Board authorized up to $100M share repurchase program; funded by working capital, no time limit.
Reaffirms cash runway into H2 2028; three Phase 1 PROTAC degraders (ARV-102, ARV-393, ARV-806) advancing.

item 2.05item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.